FDA Approves Allurion Swallowable Gastric Balloon for Obesity Treatment
Key Insights
The FDA has approved the Allurion Gastric Balloon System (search), a swallowable device that expands in the stomach without requiring surgery, endoscopy, or anesthesia for obesity (search) treatment.
The system is indicated for adults aged 22-65 with obesity (search) who have had at least one unsuccessful weight loss attempt, targeting an estimated 80 million Americans within the approved BMI range.
The balloon remains in the stomach for approximately 4 months with an average residence time of 15.3 weeks before naturally passing, with up to two balloons permitted during a 10-month period.
The US Food and Drug Administration has approved the Allurion Gastric Balloon System (search), a swallowable weight loss device that expands in the stomach without requiring surgery, endoscopy, or anesthesia. The approval expands access to an estimated 80 million Americans with obesity (search) who fall within the indicated body mass index range.
Device Administration and Mechanism
The Allurion Smart Capsule is administered during a 15-minute office visit. Once swallowed, the capsule is filled with fluid in the stomach, where it occupies space to promote satiety and reduced caloric intake. The balloon remains in place for approximately 4 months, with an average observed residence time of 15.3 weeks, before a release valve opens and the device passes naturally.
A second balloon may be placed 2 months following passage of the first, with up to two balloons permitted during a 10-month period. The system is indicated for adults aged 22 to 65 years with obesity (search) who have had at least one unsuccessful attempt at a weight loss program and must be used in conjunction with a moderate-intensity lifestyle modification therapy program.
Clinical Evidence and Real-World Experience
The device has been used in more than 200,000 patients outside of the US. In commercial settings outside the US, company-reported findings indicate 14% total body weight loss and more than 20% following 2 treatment cycles.
"The AUDACITY trial results coupled with the real-world experience outside the United States demonstrate the product's safety and efficacy," noted Shelby Sullivan, MD, a professor of medicine at the Geisel School of Medicine at Dartmouth University and the principal investigator of the US Food and Drug Administration AUDACITY pivotal trial.
Market Context and Treatment Alternative
According to Allurion Technologies, more than 100 million Americans have obesity (search), with approximately 80 million having a body mass index within the approved range. The company cited estimates that 20 million Americans have initiated and discontinued glucagon-like peptide-1 receptor agonists (search), with projections reaching 40 million by 2027. Prior studies referenced in the release reported that 65% of patients discontinued glucagon-like peptide-1 receptor agonists within the first year, primarily because of adverse effects, with subsequent weight regain.
"Our goal is to deliver patients metabolically healthy weight loss by helping them lose weight, keep it off, and maintain muscle. The Allurion Smart Capsule offers a safe and effective alternative to [glucagon-like peptide-1s] and bariatric surgery, and it should become a standard tool in the comprehensive treatment of obesity (search) in the United States," stated Shantanu Gaur, MD, Founder and Chief Executive Officer of Allurion.
The company previously paused sales of the device in France before reintroducing it last year, demonstrating the regulatory challenges and market re-entry strategies for novel medical devices in the obesity (search) treatment space.